Compromised patients

Performance beyond imagination.

Together with leading clinicians worldwide, Straumann has put to the test the SLActive® surface under the most challenging medical conditions and treatment protocols to demonstrate the extensive healing potential of SLActive®. This showed outstanding clinical performance even in severely compromised patients. Discover how you can benefit from high-performance SLActive® implants to support your patients’ healing capabilities.

  • Irradiated patients

    In a randomized clinical trial, SLActive® implants in irradiated patients showed a success rate of 100% after 1-year1 and 5-year2, 3 follow-ups.

  • Diabetic patients

    Clinical evidence shows the high predictability of SLActive® in diabetic patients.4

  • Compromised treatment sites

    In a recent preclinical study5, SLActive® showed significantly higher formation of new bone aggregate within eight weeks compared to the standard Straumann® SLA® surface.



No resources found.
See all resources...

Scientific evidence

Straumann® SLActive®

Clinical Review
490.259/en/A/00 10/16 31.10.2016 PDF, 438 KB Download


Product Catalog 2018/2019

Straumann International Edition
452.200/en/C/00 07/18 08.08.2018 PDF, 13 MB Download

International Course Calendar 2018

More than education
490.150/en/B/00 02/18 21.02.2018 PDF, 9 MB Download
See all resources...


1 Patients  treated with dental implants after surgery and radio-chemotherapy of oral cancer. Heberer S, Kilic S, Hossamo J, Raguse J-D, Nelson K. Rehabilitation of irradiated patients with modified and conventional sandblasted, acid-etched implants: preliminary results of a split-mouth study. Clin. Oral Impl. Res. 22, 2011; 546–551. 2 C. Nack, J.-D. Raguse, A. Stricker, K. Nelson & S. Nahles. Rehabilitation of irradiated patients with chemically modified and conventional SLA implants: five-year follow-up. Journal of Oral Rehabilitation 2015 42; 57—64. 3  Nelson, K., Stricker, A., Raguse, J.-D. and Nahles, S. (2016), Rehabilitation of irradiated patients with chemically modified and conventional SLA implants: a clinical clarification. J Oral Rehabil, 43: 871–872. doi:10.1111/joor.12434. 4 Machuca G., Cabrera J.J. “A prospective, case-control clinical study of titanium-zirconium alloyw implants with hydrophilic surface in patients with Type 2 diabetes mellitus” Manuscript accepted. 5 Straumann (2016). SLActive supports enhanced bone formation in a minipig surgical GBR model with coronal circumferential defects. Unpublished data